Generate evidence to quantify opportunity and justify access

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the largest and potentially the most comprehensive healthcare data resource, covering ~65 million lives, more than 99% of the French population and about 10% of Europe.

Drawing on decades of experience in real-world studies and renowned expertise in SNDS, we offer solutions for every need: from niche needs identification, justifying access, differentiating value, quantifying an opportunity to demonstrating benefit/risk.

  • Quantify Opportunity: Unmet needs, treatment patterns, burden of illness, market sizing
  • Justify Access: Cost minimization, cost offsets, cost effectiveness and budget impact analysis
  • Measure Performance: Drug utilization studies, relative effectiveness, outcomes performance, PAES
  • Ensure Safety: Benefit/risk assessment, risk management, signal detection, PASS
Quantify outcomes with patient and population-based research

Certara’s research has been instrumental in demonstrating the benefit that products and health technologies provide to patients. Certara offers real world data solutions for every need and SNDS represents a substantial part of it. Our SNDS studies are trusted by leading innovators to identify treatment patterns and patient outcomes, unmet needs among niche patient groups to target drugs, as well as burden of illness and resource utilization in the real world.

Quantify outcomes with patient and population-based research
Unmatched quality in data and analysis
Unmatched quality in data and analysis

Certara experts pioneered the use of electronic health care databases (EHCD) and electronic Medical Records (EMR) for conducting pharmaco-epidemiology studies. Our unique services link observational studies to advanced modeling in access data platforms built for bridging-to-real life studies.

Many of the typical challenges associated with conducting research using claims data can be addressed with appropriate study design and analysis using SNDS. The SNDS coverage (almost all people living in France), its universal nature and its size allow to minimize biases, long follow-up time (~10 years) and make it suitable for studying small patient populations, which is helpful when doing research on rare diseases and drug-related adverse events.

Start a Conversation
A renowned expertise in SNDS

Certara is the first, non-academic applicant to be granted access to the French SNDS database of over 65 million lives with anonymized data on socio-demographics, medical characteristics, ambulatory care, hospitalizations, diagnosis, drugs and procedures, mortality, and costs.

As key opinion leaders, Certara’s real world data specialists speak regularly at international industry events and have significant communication and publication records.

A renowned expertise in SNDS
Our Team
Sumeet Bakshi VP, Real World Data Solutions

Sumeet is VP, Real World Evidences Solutions, in Certara’s Evidence, Value & Access group. Sumeet qualified as a physician from the University of Mumbai (India) and holds an MBA from the Saïd Business School, University of Oxford (UK). Prior to joining Analytica Laser, he had gained multi-disciplinary experience working through roles in sales, brand management, and strategic planning in companies such as Pfizer and J&J.

Sumeet joined Analytica Laser (now part of Certara) in 2010 and has developed extensive expertise in real-world evidence strategies and access globally. At ANALYTICA LASER, he has set up real world research platforms for complex study programs in many therapy areas and has also consulted for clients on projects in the areas of real-world research, evidence generation strategy, strategic positioning and pricing & reimbursement strategy, amongst others.

Sumeet brings strategic thinking, insightful perspectives and strong project/program management skills to the projects that he contributes to. He is a senior member of Certara’s Evidence, Value and Access group and provides leadership to the Real World Data Solutions practice within Certara EVA.

Nadia Quignot Director, Decision Analytics & Real World Evidence

Nadia Quignot is Director, Real World Data solutions & Data analytics at Certara. Over the last >12 years, Nadia has worked on the development of methods to inform risk and benefit/risk assessment and has coordinated a range of (real world) data analytics projects, for European bodies and pharma companies. As a safety scientist at Roche Pharma, she was in charge of risk and benefit/risk evaluations for anti-inflammatory and anti-cancer drugs. In the R&D projects she conducted for European bodies, she was particularly involved in hazard characterization of drugs, pesticides and other food-related and environmental contaminants.

Nadia joined Analytica Laser in 2013 and has developed an extensive expertise in real-world evidence strategies and model-based analytics. She has been coordinating modelling initiatives and a range of (real world) data analytics projects, for European bodies and pharma companies, including directing >15 French SNDS database projects.

Nadia holds a PhD in Pharmaco/toxicometrics from Paris 5 René Descartes University.

Powered by GlobalLink OneLink Software